Scheduled infliximab monotherapy to prevent recurrence of Crohnʼs disease following ileocolic or ileal resection: A 3-year prospective randomized open trial

Abstract

An early intervention with IFX monotherapy should prevent clinical, serological, and endoscopic CD recurrence following ileocolic resection. Thiopurine naivety and eliminating the initial loading dose of IFX might minimize serious AEs.

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

“…Previous prospective clinical trials for TNF antagonists in CD have demonstrated efficacy for up to 4 years, [8][9][10] and observational and retrospective safety and efficacy data have been reported for treatment periods up to 10 years. [4][5][6][7] However, data regarding long-term patient outcomes of tolerance and efficacy in CD patients treated with anti-TNF therapy in a controlled setting remain limited.…”

“…3 To date, observational and retrospective data have been analysed for safety and efficacy for treatment periods up to 10 years [4][5][6][7] and efficacy data for prospective clinical trials have been reported for periods of up to 4 years. [8][9][10] However, the durability of remission and tolerance of patients to anti-TNF agents remains an important question in clinical practice. In particular, it is unknown whether the risk of adverse events (AE) such as serious and opportunistic infections; 11,12 malignancies, including lymphomas, melanoma and nonmelanoma skin cancer; 13 demyelinating disorders; lupus-like syndrome;…”

Adalimumab versus Infliximab in treating post-operative recurrence of Crohn’s disease: a national cohort study

“…An important limitation of this study, inherent to a retrospective study is non-uniformity in assessment of some outcome parameters. Giving the fact that the risk of postoperative recurrence increases over time, for a better evaluation of the preventive treatment for POR, a long term prospective open trial is recommended, such as the study conducted by Yoshida et al (22) showing the effectiveness of infliximab as a preventive therapy for POR in CD.…”

Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting

“…Tumor necrosis factor (TNF) antagonists (infliximab, adalimumab) have been shown to be effective in preventing post-operative recurrence of CD [17,18,19,20,21], although only in small study populations. Recently, infliximab has been shown to be more effective than placebo in preventing endoscopic but not clinical recurrence [22].…”